DOCSLIB.ORG

152 Subpart G—Packaging and Labeling Control

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
152 Subpart G—Packaging and Labeling Control § 211.115 21 CFR Ch. I (4–1–11 Edition) required to be sterile, shall be estab- contents shall be stored separately lished and followed. with suitable identification. Access to (b) Appropriate written procedures, the storage area shall be limited to au- designed to prevent microbiological thorized personnel. contamination of drug products pur- (e) Obsolete and outdated labels, la- porting to be sterile, shall be estab- beling, and other packaging materials lished and followed. Such procedures shall be destroyed. shall include validation of all aseptic (f) Use of gang-printed labeling for and sterilization processes. different drug products, or different strengths or net contents of the same [43 FR 45077, Sept. 29, 1978, as amended at 73 drug product, is prohibited unless the FR 51932, Sept. 8, 2008] labeling from gang-printed sheets is § 211.115 Reprocessing. adequately differentiated by size, shape, or color. (a) Written procedures shall be estab- (g) If cut labeling is used, packaging lished and followed prescribing a sys- and labeling operations shall include tem for reprocessing batches that do one of the following special control not conform to standards or specifica- procedures: tions and the steps to be taken to in- (1) Dedication of labeling and pack- sure that the reprocessed batches will aging lines to each different strength conform with all established standards, of each different drug product; specifications, and characteristics. (2) Use of appropriate electronic or (b) Reprocessing shall not be per- electromechanical equipment to con- formed without the review and ap- duct a 100-percent examination for cor- proval of the quality control unit. rect labeling during or after comple- tion of finishing operations; or Subpart G—Packaging and (3) Use of visual inspection to con- Labeling Control duct a 100-percent examination for cor- rect labeling during or after comple- § 211.122 Materials examination and tion of finishing operations for hand- usage criteria. applied labeling. Such examination (a) There shall be written procedures shall be performed by one person and describing in sufficient detail the re- independently verified by a second per- ceipt, identification, storage, handling, son. sampling, examination, and/or testing (h) Printing devices on, or associated of labeling and packaging materials; with, manufacturing lines used to im- such written procedures shall be fol- print labeling upon the drug product lowed. Labeling and packaging mate- unit label or case shall be monitored to rials shall be representatively sampled, assure that all imprinting conforms to and examined or tested upon receipt the print specified in the batch produc- and before use in packaging or labeling tion record. of a drug product. [43 FR 45077, Sept. 29, 1978, as amended at 58 (b) Any labeling or packaging mate- FR 41353, Aug. 3, 1993] rials meeting appropriate written spec- ifications may be approved and re- § 211.125 Labeling issuance. leased for use. Any labeling or pack- (a) Strict control shall be exercised aging materials that do not meet such over labeling issued for use in drug specifications shall be rejected to pre- product labeling operations. vent their use in operations for which (b) Labeling materials issued for a they are unsuitable. batch shall be carefully examined for (c) Records shall be maintained for identity and conformity to the labeling each shipment received of each dif- specified in the master or batch pro- ferent labeling and packaging material duction records. indicating receipt, examination or (c) Procedures shall be used to rec- testing, and whether accepted or re- oncile the quantities of labeling issued, jected. used, and returned, and shall require (d) Labels and other labeling mate- evaluation of discrepancies found be- rials for each different drug product, tween the quantity of drug product fin- strength, dosage form, or quantity of ished and the quantity of labeling 152 VerDate Mar<15>2010 13:10 May 12, 2011 Jkt 223068 PO 00000 Frm 00162 Fmt 8010 Sfmt 8010 Y:\SGML\223068.XXX 223068 WReier-Aviles on DSKGBLS3C1PROD with CFR Food and Drug Administration, HHS § 211.132 issued when such discrepancies are out- (e) Inspection of the packaging and side narrow preset limits based on his- labeling facilities immediately before torical operating data. Such discrep- use to assure that all drug products ancies shall be investigated in accord- have been removed from previous oper- ance with § 211.192. Labeling reconcili- ations. Inspection shall also be made to ation is waived for cut or roll labeling assure that packaging and labeling ma- if a 100-percent examination for correct terials not suitable for subsequent op- labeling is performed in accordance erations have been removed. Results of with § 211.122(g)(2). inspection shall be documented in the (d) All excess labeling bearing lot or batch production records. control numbers shall be destroyed. [43 FR 45077, Sept. 29, 1978, as amended at 58 (e) Returned labeling shall be main- FR 41354, Aug. 3, 1993] tained and stored in a manner to pre- vent mixups and provide proper identi- § 211.132 Tamper-evident packaging fication. requirements for over-the-counter (f) Procedures shall be written de- (OTC) human drug products. scribing in sufficient detail the control (a) General. The Food and Drug Ad- procedures employed for the issuance ministration has the authority under of labeling; such written procedures the Federal Food, Drug, and Cosmetic shall be followed. Act (the act) to establish a uniform na- tional requirement for tamper-evident [43 FR 45077, Sept. 29, 1978, as amended at 58 packaging of OTC drug products that FR 41354, Aug. 3, 1993] will improve the security of OTC drug packaging and help assure the safety § 211.130 Packaging and labeling oper- ations. and effectiveness of OTC drug products. An OTC drug product (except a der- There shall be written procedures de- matological, dentifrice, insulin, or loz- signed to assure that correct labels, la- enge product) for retail sale that is not beling, and packaging materials are packaged in a tamper-resistant pack- used for drug products; such written age or that is not properly labeled procedures shall be followed. These under this section is adulterated under procedures shall incorporate the fol- section 501 of the act or misbranded lowing features: under section 502 of the act, or both. (a) Prevention of mixups and cross- (b) Requirements for tamper-evident contamination by physical or spatial package. (1) Each manufacturer and separation from operations on other packer who packages an OTC drug drug products. product (except a dermatological, den- (b) Identification and handling of tifrice, insulin, or lozenge product) for filled drug product containers that are retail sale shall package the product in set aside and held in unlabeled condi- a tamper-evident package, if this prod- tion for future labeling operations to uct is accessible to the public while preclude mislabeling of individual con- held for sale. A tamper-evident pack- tainers, lots, or portions of lots. Identi- age is one having one or more indica- fication need not be applied to each in- tors or barriers to entry which, if dividual container but shall be suffi- breached or missing, can reasonably be cient to determine name, strength, expected to provide visible evidence to quantity of contents, and lot or control consumers that tampering has oc- number of each container. curred. To reduce the likelihood of suc- (c) Identification of the drug product cessful tampering and to increase the with a lot or control number that per- likelihood that consumers will discover mits determination of the history of if a product has been tampered with, the manufacture and control of the the package is required to be distinc- batch. tive by design or by the use of one or (d) Examination of packaging and la- more indicators or barriers to entry beling materials for suitability and that employ an identifying char- correctness before packaging oper- acteristic (e.g., a pattern, name, reg- ations, and documentation of such ex- istered trademark, logo, or picture). amination in the batch production For purposes of this section, the term record. ‘‘distinctive by design’’ means the 153 VerDate Mar<15>2010 13:10 May 12, 2011 Jkt 223068 PO 00000 Frm 00163 Fmt 8010 Sfmt 8010 Y:\SGML\223068.XXX 223068 WReier-Aviles on DSKGBLS3C1PROD with CFR.
Load more

Recommended publications
  • Getinge Pack Tyvek Sterilization Reels and Pouches
    SAFETY DATA SHEET Getinge Pack Tyvek Sterilization Reels and Pouches 1.0 Product Product Name Getinge Pack Tyvek Sterilization Reels and Pouches and Company Product Code Tyvek Reel (TY)- Tyvek Pouch (TP) Identification Intended Use Tyvek Sterilization Reels and Pouches are intended to be used to enclose another medical devices that are to be sterilized by health care provider via related sterilization methods. Supplier PMS Tıbbi Cihazlar Teknolojisi Sanayi ve Ticaret A.Ş Identification Address Karaduvar Mah. Serbest Bölge 11. Cadde No: 46,Akdeniz, 33020 Mersin/TURKEY Phone +90 324 238 70 42 Fax +90 324 238 65 49 2.0 Hazards Tyvek material and PET/PE laminated film are not classified as dangerous according to EC directives and other international safety guidelines. Identification 3.0 Composition Information on Ingredients • Tyvek Material (1059B, 64.4 g/m² ) / Information on • Polyethylene Terephthalate / Polyethylene (PET/PE) Laminated Film Ingredients 12/50 microns • Printing inks, Indicator inks 4.0 First Aid Eye contact If molten material or dust contacts the eye, immediatly flush Measures with plenty of water for at least 15 minutes. If easy to do , remove contact lenses. Get medical attention immediately. Skin contact If contact with molten product occurs, treat as for thermal burn. Cool melted product on skin with plenty of water. Do not remove solidified product. If dust contacts the skin, immediately flush with plenty of water. Inhalation Remove patient to fresh air. Seek medical attention if necessary. Ingestion Material is not expected to be absorbed from the gastrointestinal tract. However, the printing chemicals such as printing inks and chemical indicator inks could be harmful.
    [Show full text]
  • Coa Ng Conver Ng Distribu
    s! t Last Tha ond A B Self-Adhesive Tapes Electrical Insula� on Tapes Industrial Tapes Packaging Tapes Double Sided Tapes Die-Cut Solu� ons Specialty Tapes Dispensers & Processing Devices Coa� ng Conver� ng Distribu� on Volz Selbstklebetechnik GmbH YOUR EXPERT IN ADHESIVE TAPE SOLUTIONS VOLZ® TAPES is your competent partner for all self-adhesive tape requirements. Our extensive product por� olio offers a variety of standard and specialty tape products, suppor� ng advanced industry applica� ons, as well as standard and complex packaging require- ments. We are the industry expert in double-sided tapes, electrical and industrial tapes, packaging tapes, self-adhesive die-cut solu� ons, as well as tape dispensers and processing devices. VOLZ® TAPES has spent the last several decades developing its core competencies in the areas of Coa� ng, Conver� ng and Distribu� on. We produce turn-key custom tape solu� ons to meet our customers’ most complex industry challenges. Our advanced produc� on facility is capable of cu� ng any tape width or producing die-cut solu� ons to your exact specifica� ons. It is our goal to develop high-end, cost effec� ve tape solu� ons that meet your opera� onal demands. VOLZ® TAPES is an ac� ve and trusted member of AFERA, the European Adhesive Tape Associa� on. AFERA membership provides a front row seat to market developments and valuable exposure to other key adhesive tape associa� ons such as PSTC (USA), CATIA (China), TAAT (Taiwan) and JATMA (Japan). • Coa� ng of diverse carrier materials such as Fabric, PP, PE, PET, PVC, Fleece and COATING: CUSTOMIZED ADHESIVE SOLUTIONS Foam VOLZ® TAPES develops and manufactures high-end electrical and • Available Adhesives Include: double-sided adhesive tapes.
    [Show full text]
  • Supply Chain Packaging Guide
    Secondary Packaging Supply Chain Standards July 7, 2021 Business Confidential | ©2021 Walmart Stores, Inc. 177 // 338 Secondary Packaging Supply Chain Standards - Update Summary These standards have included multiple clarifications of what is required and what is NOT ALLOWED. These changes have been updated throughout the published standards to provide clarity to suppliers. The pages have been reorganized to provide a better flow. PAGE 2021 UPDATES Changes to Supply Chain Standards 185 SQEP Phase 2 and Phase 3 Defect Description/Definitions Added 202 General Case Markings Updated for Dates, Unprocessed Meats, and Cylindrical Items 210-213 Updated Pallet Standards 218 Update "Palletized Shipments" to "Unitized Shipments" 227 Add Inbound Appointment Scheduling Standard 228 Update TV Test Standards 235-237 Add Direct Store Delivery (DSD) aka Direct To Store (DTS) Standards 239 Update SIOC Standards 240 Add eCommerce Product Specific Requirement Standards 241-244 Add Drop Ship Vendor (DSV) Standards 268 Add Jewelry Distribution Center Standards 269-271 Add Optical Distribution Center Standards 275 Add Goods Not For Resale (GNFR) Standards 277-278 Update Meat/Poultry/Seafood Case and Pallet Label Standards 284 Add HACCP Pallet Placard for GCC Shipments 311-312 Add Frozen Seafood Carton Marking Requirements Appendix D Update Receiving Pulp Temperature Range Business Confidential | © 2021 Walmart Stores, Inc. The examples shown are for reference only. Supply Chain Standards 178 // 338 Table of Contents Supply Chain Stretch Wrap . 219 Produce Shipments . 280 Contact Information . 179 Trailer Loading . 220 Automated Grocery Handling . 281 Walmart Retail Link Resources . 180 Trailer Measurements. 221 Grocery Import Distribution Center (GIDC) . 282 Walmart Distribution Center Overview .
    [Show full text]
  • 10 Things Packaging Engineers Should Know
    EU MDR 10 Things Packaging Engineers Should Know networkpartners.com THE TIME FOR ACTION IS NOW NUMBER ONE First, some background: The EU Medical Device Regulation (MDR) was approved by the European Parliament on April 5, 2017 and, following its formal adoption, was published in the Official Journal of the EU on May 26, 2017. This means that the MDR will be fully enforceable on May 26, 2020. The first step in this process is for Notified Bodies (NBs) to apply for designation under the MDR, meaning NBs must receive approval from the European Commission before they can assess the conformity of products and before those products can be placed on the market. NBs can apply for designation on Nov 26, 2017, and the process could take nine to 12 months. It may be advisable to check with your NBs to understand their timelines and capacity. Not all NBs will apply for designation or be able to comply with the increased requirements. After an NB has been designated they can start conducting conformity assessments and certifying products to the MDR. To sell or continue to sell medical devices in the European Union, a CE mark indicating certification is required. There is no provision for grandfathering CE marks under the previous directives – all products sold in the EU must be CE marked under the Regulation 2017/745. The timeline for MDR implementation is 3 years, starting January 2018 and ending May 2020. There is a grace period for certificates granted under the prior directive which extends to June 2024. Although packaging continues to be considered an accessory to a medical device, packaging and labeling are specifically addressed in the EU MDR and need to be included in your company’s overall compliance timeline.
    [Show full text]
  • (Cgmp) for Drugs
    Questions and Answers on Current Good Manufacturing Practices, Goo... http://www.fda.gov/cder/guidance/cGMPs/packaging.htm FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER Questions and Answers on Current Good Manufacturing Practices, Good Guidance Practices, Level 2 Guidance Packaging and Labeling Control 1. Do CGMPs require that forced degradation studies always be conducted of the drug product when determining if a drug product stability test method is stability- indicating? 2. Can containers, closures, and packaging materials be sampled for receipt examination in the warehouse? 1. Do CGMPs require that forced degradation studies always be conducted of the drug product when determining if a drug product stability test method is stability- indicating? No. Drug product stress testing (forced degradation) may not be necessary when the routes of degradation and the suitability of the analytical procedures can be determined through use of the following: data from stress testing of drug substance reference materials for process impurities and degradants data from accelerated and long-term studies on drug substance data from accelerated and long-term studies on drug product Additional supportive information on the specificity of the analytical methods and on degradation pathways of the drug substance may be available from literature sources. Section 211.165(e) of the CGMP regulations states that the accuracy, sensitivity, specificity, and reproducibility of test methods shall be established and documented. Further, section 211.166(a)(3) requires that stability test methods be reliable, meaningful, and specific, which means that the content of active ingredient, degradation products, and other components of interest in a drug product can be accurately measured without interference, often called "stability-indicating." The CGMP regulations do not specify what techniques or tests are to be used to ensure that one’s test methods are stability-indicating.
    [Show full text]
  • The Office of Cannabis Regulation Packaging and Labeling Guide for Medical Marijuana Version 1 March 2020
    State of Rhode Island and Providence Plantations DEPARTMENT OF BUSINESS REGULATION Office of Cannabis Regulation 1511 Pontiac Avenue, Bldg. 68-1 Cranston, Rhode Island 02920 The Office of Cannabis Regulation Packaging and Labeling Guide for Medical Marijuana Version 1 March 2020 This document is meant to help explain the packaging and labeling rules effective on March 25, 2020. However, this guide should not replace a thorough reading of the rules found here: https://rules.sos.ri.gov/regulations/part/230-80-05-1. 1 Table of Contents Product Type Page Number Flower Packaging 3 Labeling 4 Concentrate Packaging and Device 6 Labeling 7 Edible Single Serving- Solid 9 Multiple Single Serving- Solid 10 Single Serving- Liquid 11 Multiple Single Serving- Liquid 12 Bundled 13 Labeling 14 Ingestible Single Serving- Solid 16 Multiple Single Serving- Solid 17 Single Serving- Liquid 18 Multiple Single Serving- Liquid 19 Bundled 20 Labeling 21 Child-Resistant 23 Exit Packaging 24 Universal Symbol Stamping 25 2 Flower Packaging Requirements Packaging must be: • Opaque. • Light-Resistant. • Tamper- Evident. • Neutral in Color. • Certified as Child-Resistant (see page 24 for additional requirements). • Resealable. Confirm the Packaging: • Protects the product from contamination. • Does not impart any toxic or deleterious substance to the product. • Fully encloses the product. • Does not contain any design, image, label or coloring that was not approved or required by the OCR. 3 Flower Labeling Requirements Font Requirements for required information: • No smaller than size 6 font. • Permitted Font Types: Times New Roman, Calibri, Arial, Helvetica. • Must be in Black or White. • Clearly printed in the English language.
    [Show full text]
  • PACKAGING and LABELING UPDATE for MEDICAL and RECREATIONAL MARIJUANA – August 15, 2018
    PACKAGING AND LABELING UPDATE FOR MEDICAL AND RECREATIONAL MARIJUANA – August 15, 2018 INTRODUCTION This update highlights changes in the packaging and labeling rules that took effect August 15, 2018. This document is not a substitute for licensees having a thorough understanding of the OLCC’s marijuana packaging and labeling rules. All licensees and registrants are required to follow and understand the packaging and labeling rules. Read the specific rules at: OAR 845- 025-7000 – 845-025-7190. EFFECTIVE DATE AND “SELL DOWN PERIOD” On August 15, 2018, new packaging and labeling rules went into effect. As a result the status of all labels approved before August 15, 2018 have been changed to “Resubmission Required.” Producers, processors, and wholesalers must transfer all of their previously approved label inventory to retailers before April 1, 2019. If they do not, the product will have to be relabeled or destroyed. Retailers may sell down products with previously approved labels through December 31, 2019. Starting January 1, 2020, marijuana items and industrial hemp commodities and products with labels approved prior to August 15, 2018, can no longer be sold, offered for sale, or transferred to a consumer, patient, or designated primary caregiver. Read the specific rules at: OAR 845-025-7190. LABEL ID All labels approved by the Commission must have a label identification number displayed on the outermost container. The format is “Label ID:” and you may use a placeholder number when submitting a label application, for example “Label ID: 0000.” However, your final label must have an accurate Label ID number. If you are using a generic label, you do not receive a Label ID.
    [Show full text]
  • He-C 402 Therapeutic Cannabis Program
    RULEMAKING NOTICE FORM Notice Number 2014-140 Rule Number He-C 402 1. Agency Name & Address: 2. RSA Authority: RSA 126-X:6, III(a) 3. Federal Authority: NH Department of Health and Human Services Bureau of Licensing and Certification 4. Type of Action: Health Facility Licensing Unit Adoption X Therapeutic Cannabis Program Amendment 129 Pleasant Street Repeal Concord, NH 03301 Readoption Readoption w/amendment 5. Short Title: Therapeutic Cannabis Program – Alternative Treatment Centers 6. (a) Summary of what the rule says and of any proposed amendments: He-C 402 is a new rule which implements a portion of HB 573 from the 2013 legislative session (Chapter 232 of the Laws of 2013), relative to the use of cannabis for therapeutic purposes. The enabling law, RSA 126-X, creates an exemption in state law from criminal penalties for the therapeutic use of cannabis provided that its use is in compliance with RSA 126-X. The NH Legislature placed the responsibility for administering the program within the NH Department of Health and Human Services. He-C 402 sets forth the requirements necessary to establish, operate, and maintain an alternative treatment center (ATC) for the purposes of cultivating, processing, packaging, labeling, and dispensing therapeutic cannabis to qualifying patients or their designated caregivers. These requirements include the following: fees; registration application and renewal requirements; requirements for organizational of service changes; policy and procedure requirements; operational requirements; permitted quantities
    [Show full text]
  • PACKAGING and LABELING BRANDING TRANSITION July 2018
    PACKAGING AND LABELING BRANDING TRANSITION July 2018 © 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. Merck, the vibrant M, Sigma-Aldrich, BioReliance, Supelco, SAFC, Milli-Q, Millipore are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. Packaging and labeling branding transition Overview At Merck, we are rebranding all product packaging, labeling, and related documentation to reflect consistent corporate branding and relevant portfolio branding. What Why • Follows the launch of the new Merck brand in 2015 Updating packaging and label Additional changes include: and the integration of Sigma-Aldrich into our Life materials on all 300,000 of our Science business, the largest acquisition in our products, including: • Adding 2D Data Matrix Global Standards One (GS1) barcodes to history. • Shipping boxes most of our labels. • Ensures that our products and packaging are visibly, • Product and kit boxes • Enhancing the sustainability boldly and undeniably Merck and that you will start to • Labels on devices, bottles, product characteristics of our packaging. see a consistent brand presence across the entirety of and shipping boxes • Adding a new security feature to our the life science business of Merck. • Packaging materials (such as labels to ensure the authenticity of branded bottles, films, bags, packing our products. When tape and drums) • Updating labels and documentation • You may start receiving newly-branded products in • Branding of product documentation for legacy Merck Millipore products the coming months. (such as certificates of quality and that currently reference the 290 • We expect to make significant progress over the analysis, handling instructions, Concord Rd, Billerica, MA address to course of 2018.
    [Show full text]
  • Auditing a Packaging and Labeling Operation Sample
    Auditing a Packaging and Labeling Operation Goals When you have completed this module, you should be able to: • Perform a packaging and labeling audit. • Know and understand which of the worldwide requirements apply to packaging and labeling operations. • Use a range of information tools, including the contents of this module to the Intranet, in support of a packaging and labeling audit. • Recognize compliance or non-compliance of regulations pertaining to packaging and labeling requirements. Definitions Blinding: A procedure in which one or more parties to the Clinical Study are kept unaware of the treatment assignment(s) until code break after clean file. Cleaning: Operation which terminates a production process, incl. dismantling and wet cleaning of the equipment as well as removal of all materials, products and documentation from the equipment and room/surrounding area. The cleaning must be finished by a documented check by a second person. Cut labeling: labels that have been cut from a sheet and are individual labels. Gang-printed labeling: labeling derived from a sheet of material on which more than one item of labeling is printed. (see example below) Line-clearance: Operation which must be made immediately before a production process is started. Line-clearance includes: • Verifying that the Cleaning has been performed at termination of the previous batch • A documented check that the equipment/area is still in a clean status The operation above must be performed by a person not involved in the Cleaning of the line/area. Over-labeling: The addition of a label, usually to a primary pack or carton, to obscure the original labeling and supersede it with the text on the added label.
    [Show full text]
  • Supplier Packaging and Labeling Manual
    Supplier Packaging and Labeling Manual Page 1 of 5 May 2016 Table of Contents 1. Introduction 2. Corrugated Specifications for all Shipments 2.1 Special handling 2.2 Master Carton Label 3. Packing Slip 4. Pallet Requirements 4.1 Pallet Standards 4.2 Pallet Label 4.3 Pallet Overhang 5. Routing Instructions Page 2 of 5 May 2016 1. Introduction This manual is designed to inform Enovation Controls supplier partners of our packaging and shipping guidelines. Please follow the steps outlined below to ensure that our parts are packed, protected, and shipped in an efficient manner 2. Corrugate Specifications • Both single-wall and double-wall corrugated containers are acceptable, provided they meet the strength requirements detailed on the Box Makers Certificate • Corrugated packaging shall be able to withstand multiple stacking of pallet loads. • The total weight of each carton shall not exceed 50 lbs. (22.6 kg) • Supplier shall do their best to ensure that each carton has equal weight distribution. • Cartons will be packed as efficiently as possible. Do not use an oversized carton and fill the void with packaging material. Please make sure to always use right-sized cartons. 2.1 Special Handling (LCD/Glass/Ceramic) • The fragile items listed above must require additional packaging to reduce the chances for damage. • Product should always be shipped in a carton with corrugated partitions. Product should never run the risk of coming into contact with another product during shipment. • Each individual piece must be wrapped in some type of protective wrap (Anti-static when applicable) to prevent damage. • When stacking multiple corrugated partitions, use a corrugate divider to ensure the layers of product stay separate.
    [Show full text]
  • Industry Guide to Marketing Container Plants
    Industry Guide To Marketing Container Plants Purpose of the guide This publication is intended to provide guidance to industry retailers and their suppliers on the minimum information required by law in selling “packaged products,” including containerized plants. This guide summarizes the law and regulations about what types of information are required and how that information must be presented. Where possible, this guide offers specific suggestions on how businesses in the horticulture industry can meet these requirements that have been in the law for a number of years, but are just now coming to the industry’s attention. Origin of t his Guide With the dramatic increase in container plants sales, state and related weights and measures compliance staff have stepped up their scrutiny of industry marketing practices. These authorities have discovered that some long-time practices in the industry regarding labeling and advertising violate or ignore consumer information requirements. They have warned the industry that it must come into compliance. Retailers not in compliance can incur stop-sale orders and substantial fines and penalties for misleading or inadequate labeling and advertising. The industry is responding to their warning. Labeling and signage practices in this industry affect businesses along the entire supply chain, from container and label manufacturers, to growers and plant branding firms, to the ultimate retailer. National trade associations representing businesses along the supply chain have appointed multiple task forces to research the law, identify common areas of non-compliance, and develop guidelines to assist industry businesses in conforming to the law. Following all these recommendations addresses compliance with these regulations as they are understood, and strict compliance is strongly encouraged.
    [Show full text]